RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D (RISK)
Sponsor: Abbott Medical Devices
A observational or N/A phase clinical study on Heart Failure, this trial is completed. The trial is conducted by Abbott Medical Devices and has accumulated 12 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Study Description(click to expand)Primary Endpoint The primary endpoint is the occurrence of either death or first HF hospitalization. HF hospitalizations must satisfy both of the following criteria: 1. Admission to hospital for \>24 hours with at least one of the following HF worsening symptoms: * Increased CHF class * Orthopnea * Paroxysmal nocturnal dyspnea * Edema * Dyspnea on exertion, or * Gastrointestinal (GI) symptoms attributable to HF * Placement on the Status I heart transplant list AND 2. One or more of the following intensive treatment(s) for HF within 24 hours of admission: * Intravenous (IV) diuresis * IV inotropic medications prescribed during the hospitalization, or * Increasing frequency of dialysis for patients with chronic renal failure 2.3 Secondary Endpoints Secondary endpoints include: * Cause of death * Change in NYHA functional class * Number of HF related hospitalizations * Performance on a standard 6-minute hall walk test * Quality of Life as measured by the Minnesota Living with Heart Failure (MLWHFQ) questionnaire * Patient global clinical assessment * Left ventricular ejection fraction (LVEF) measured by echocardiography * LV volume measured by echocardiography * LV lead placement position * QRS duration at baseline and with CRT * Number of AT/AF, VT/VF episodes...
Primary Endpoint
The primary endpoint is the occurrence of either death or first HF hospitalization. HF hospitalizations must satisfy both of the following criteria:
1. Admission to hospital for \>24 hours with at least one of the following HF worsening symptoms:
* Increased CHF class * Orthopnea * Paroxysmal nocturnal dyspnea * Edema * Dyspnea on exertion, or * Gastrointestinal (GI) symptoms attributable to HF * Placement on the Status I heart transplant list
AND 2. One or more of the following intensive treatment(s) for HF within 24 hours of admission:
* Intravenous (IV) diuresis * IV inotropic medications prescribed during the hospitalization, or * Increasing frequency of dialysis for patients with chronic renal failure
2.3 Secondary Endpoints
Secondary endpoints include:
* Cause of death * Change in NYHA functional class * Number of HF related hospitalizations * Performance on a standard 6-minute hall walk test * Quality of Life as measured by the Minnesota Living with Heart Failure (MLWHFQ) questionnaire * Patient global clinical assessment * Left ventricular ejection fraction (LVEF) measured by echocardiography * LV volume measured by echocardiography * LV lead placement position * QRS duration at baseline and with CRT * Number of AT/AF, VT/VF episodes * Frequency of appropriate/inappropriate ICD therapy * % Atrial and Ventricular Pacing * Antiarrhythmic drug utilization * Study related complications
2.3.1 Response to CRT
1. A positive response to CRT is defined by the following: Improvement in NYHA functional class by at least one grade 2. Improvement in echocardiographic LVEF \& left ventricular end diastolic index (LVEDI) 3. Improvement in patient global clinical assessment 4. Improvement in 6-minute hall walk by 10%
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 7 earlier versions
-
Mar 2019 — Nov 2020 [monthly]
Completed
-
Feb 2019 — Mar 2019 [monthly]
Completed
-
Jun 2018 — Feb 2019 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Aug 2017 — Apr 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE4
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- VA Pittsburgh Healthcare System
For direct contact, visit the study record on ClinicalTrials.gov .